Log In
BCIQ
Print this Print this
 

hCMV mAb (CSJ148)

  Manage Alerts
Collapse Summary General Information
Company Humabs BioMed S.A.
DescriptionHuman cytomegalovirus (hCMV) neutralizing human mAb
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsTreat cytomegalovirus (CMV)
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/01/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today